These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

920 related items for PubMed ID: 10811338

  • 1. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis.
    Cohen RD, Woseth DM, Thisted RA, Hanauer SB.
    Am J Gastroenterol; 2000 May; 95(5):1263-76. PubMed ID: 10811338
    [Abstract] [Full Text] [Related]

  • 2. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis.
    Sinha A, Nightingale J, West KP, Berlanga-Acosta J, Playford RJ.
    N Engl J Med; 2003 Jul 24; 349(4):350-7. PubMed ID: 12878742
    [Abstract] [Full Text] [Related]

  • 3. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group.
    Ardizzone S, Doldo P, Ranzi T, Sturniolo GC, Giglio LA, Annese V, D'Arienzo A, Gaia E, Gullini S, Riegler G, Valentini M, Massa P, Del Piano M, Rossini F, Guidetti CS, Pera A, Greinwald R, Bianchi Porro G.
    Ital J Gastroenterol Hepatol; 1999 Nov 24; 31(8):677-84. PubMed ID: 10730559
    [Abstract] [Full Text] [Related]

  • 4. Ulcerative proctitis: a review of pharmacotherapy and management.
    Lakatos PL, Lakatos L.
    Expert Opin Pharmacother; 2008 Apr 24; 9(5):741-9. PubMed ID: 18345952
    [Abstract] [Full Text] [Related]

  • 5. Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis.
    Cortot A, Maetz D, Degoutte E, Delette O, Meunier P, Tan G, Cazals JB, Dewit O, Hebuterne X, Beorchia S, Grunberg B, Leprince E, D'Haens G, Forestier S, Idier I, Lémann M.
    Am J Gastroenterol; 2008 Dec 24; 103(12):3106-14. PubMed ID: 19086960
    [Abstract] [Full Text] [Related]

  • 6. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.
    Segars LW, Gales BJ.
    Clin Pharm; 1992 Jun 24; 11(6):514-28. PubMed ID: 1600685
    [Abstract] [Full Text] [Related]

  • 7. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis.
    Sandborn WJ, Korzenik J, Lashner B, Leighton JA, Mahadevan U, Marion JF, Safdi M, Sninsky CA, Patel RM, Friedenberg KA, Dunnmon P, Ramsey D, Kane S.
    Gastroenterology; 2010 Apr 24; 138(4):1286-96, 1296.e1-3. PubMed ID: 20064514
    [Abstract] [Full Text] [Related]

  • 8. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis.
    Hanauer S, Good LI, Goodman MW, Pizinger RJ, Strum WB, Lyss C, Haber G, Williams CN, Robinson M.
    Am J Gastroenterol; 2000 Jul 24; 95(7):1749-54. PubMed ID: 10925979
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis.
    Ford AC, Khan KJ, Sandborn WJ, Hanauer SB, Moayyedi P.
    Clin Gastroenterol Hepatol; 2012 May 24; 10(5):513-9. PubMed ID: 22083024
    [Abstract] [Full Text] [Related]

  • 10. Maintenance oral sulfasalazine prolongs remission in ulcerative proctitis and proctosigmoiditis.
    LaRosa D, Rubin PH, Bodian C, Present DH.
    Am J Gastroenterol; 1991 Oct 24; 86(10):1456-60. PubMed ID: 1681725
    [Abstract] [Full Text] [Related]

  • 11. Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study.
    Richter JM, Kushkuley S, Barrett JA, Oster G.
    Aliment Pharmacol Ther; 2012 Aug 24; 36(3):248-56. PubMed ID: 22690748
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of clinical patterns in ulcerative colitis: a long-term follow-up.
    Bresci G, Parisi G, Gambardella L, Banti S, Bertoni M, Rindi G, Capria A.
    Int J Clin Pharmacol Res; 1997 Aug 24; 17(1):17-22. PubMed ID: 9403349
    [Abstract] [Full Text] [Related]

  • 13. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
    Sandborn WJ.
    Rev Gastroenterol Disord; 2006 Aug 24; 6(2):97-105. PubMed ID: 16699478
    [Abstract] [Full Text] [Related]

  • 14. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.
    Pruitt R, Hanson J, Safdi M, Wruble L, Hardi R, Johanson J, Koval G, Riff D, Winston B, Cross A, Doty P, Johnson LK.
    Am J Gastroenterol; 2002 Dec 24; 97(12):3078-86. PubMed ID: 12492193
    [Abstract] [Full Text] [Related]

  • 15. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
    Dignass AU, Bokemeyer B, Adamek H, Mross M, Vinter-Jensen L, Börner N, Silvennoinen J, Tan G, Pool MO, Stijnen T, Dietel P, Klugmann T, Vermeire S, Bhatt A, Veerman H.
    Clin Gastroenterol Hepatol; 2009 Jul 24; 7(7):762-9. PubMed ID: 19375519
    [Abstract] [Full Text] [Related]

  • 16. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
    Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, Regalli G, Yeh C, Smith-Hall N, Ajayi F.
    Am J Gastroenterol; 2005 Nov 24; 100(11):2478-85. PubMed ID: 16279903
    [Abstract] [Full Text] [Related]

  • 17. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.
    Hanauer S, Schwartz J, Robinson M, Roufail W, Arora S, Cello J, Safdi M.
    Am J Gastroenterol; 1993 Aug 24; 88(8):1188-97. PubMed ID: 8338086
    [Abstract] [Full Text] [Related]

  • 18. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU).
    Fernández-Bañares F, Hinojosa J, Sánchez-Lombraña JL, Navarro E, Martínez-Salmerón JF, García-Pugés A, González-Huix F, Riera J, González-Lara V, Domínguez-Abascal F, Giné JJ, Moles J, Gomollón F, Gassull MA.
    Am J Gastroenterol; 1999 Feb 24; 94(2):427-33. PubMed ID: 10022641
    [Abstract] [Full Text] [Related]

  • 19. Mesalamine with MMX technology for the treatment of ulcerative colitis.
    Schreiber S, Kamm MA, Lichtenstein GR.
    Expert Rev Gastroenterol Hepatol; 2008 Jun 24; 2(3):299-314. PubMed ID: 19072380
    [Abstract] [Full Text] [Related]

  • 20. Can oral 5-aminosalicylic acid be administered once daily in the treatment of mild-to-moderate ulcerative colitis? A meta-analysis of randomized-controlled trials.
    Zhu Y, Tang RK, Zhao P, Zhu SS, Li YG, Li JB.
    Eur J Gastroenterol Hepatol; 2012 May 24; 24(5):487-94. PubMed ID: 22465970
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.